Quazinone

Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3) . Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect [1].

Product Specifications

CAS Number

[70018-51-8]

Product Name Alternative

Ro 13-6438; Ro 13-6438/006

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAPKAPK2 (MK2) ; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/quazinone.html

Purity

99.7

Solubility

10 mM in DMSO

Smiles

C[C@H]1N2C(NC3=CC=CC(Cl)=C3C2)=NC1=O

Molecular Formula

C11H10ClN3O

Molecular Weight

235.67

Precautions

H302, H315, H319, H335

References & Citations

[1]A Taher, et al. Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol. 1994;12 (5) :286-91.|[2]M T Osinski, et al. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem Pharmacol. 2000 Aug 1;60 (3) :381-7.